Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years
Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years
Active, not recruiting · NCT05776888 · Registry updated 2025-12-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years | Relapsing Multiple Sclerosis | Active, not recruiting | Not stated | 2025-12-30 | NCT05776888 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Novartis Pharmaceuticals | 432 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||